Outsourcing STREAM

1. Increase The Titer Of A Difficult To Express Molecule 12/11/2019

   What happens if you have a promising molecule but can’t engineer a cell line to deliver the titer needed to support clinical development?  A low process titer may render the molecule, such as an antibody, too costly to manufacture and unsuitable for continued investment. Learn how our client achieved a nearly 4-fold titer increase.

2. MilliporeSigma Large Scale Capabilities Tour 10/20/2021

   A detailed look at MilliporeSigma’s new BioReliance® viral vector manufacturing facility and how we have employed the latest innovations and quality systems to deliver best-in-class gene therapy services.

3. Increasing The Reach Of Cell And Gene Therapies 4/29/2021

   The cell and gene therapy industry is rapidly evolving from the perspective of “can we commercialize this class of therapeutics?” to “how do we reach patients who need these therapies?”. However, the promise of these biologics can only be realized if the industry approaches manufacturing parity with monoclonal antibodies. A mixture of innovation and brute-force streamlining is needed to create viable cell and gene therapy templates. In this video, we discuss how upstream process optimization is ripe for innovative approaches.

4. A Dedicated Team To Safely Store Your Cell And Virus Banks 2/27/2023

   The safety of your cell and virus banks must be your top priority. Learn about a team dedicated to the safety of your material along with their related services.

5. Collaboration & Expertise, The Keys To Efficiency And Scalability Across All Modalities 7/8/2022

   View this video and discover our global vaccine capabilities from process development to full-scale GMP-manufacturing and in all modalities.

6. Accelerate Identification Of High-Producing Cell Lines 12/11/2019

   When companies are putting in place an upstream process, a critical step is generation of a cell line expressing the protein of interest. Unfortunately, the search for the best-producing clone is often compared with looking for a needle in a haystack. Watch our video to learn about our mini-pool approach and the value of automated systems to efficiently create, screen and isolate high producing clones with reduced costs.

7. How MilliporeSigma Promotes Quality And Risk Reduction 10/20/2021

   Learn how MilliporeSigma’s new facility was built with quality and risk reduction at the top of mind and its experts have the experience to support large-scale programs through commercialization.

8. Commercial Readiness with Orca Bio's Dan Kirby 9/14/2023

   Orca Bio's Dan Kirby has played a hand in prepping more than a few approved biologic therapeutic candidates for commercialization. Equally important, he knows firsthand what makes or breaks post-approval commercial efforts, having played virtually every role there is to play in drug sales and marketing.

9. Thermo Fisher Scientific Customer Testimonial - Libbs 9/20/2018

   An overview of Libbs product portfolio and how they benefit from Thermo Fisher Scientific services.

10. How To Generate A High-Producing Cell Line In Fast-Track Mode 12/11/2019

    Cell line development processes can be quite time consuming and labor intensive. When our clients have a very challenging timeline, we can begin process development in parallel with cell line development, further accelerating timelines. What are the risks and how do you minimize risk?